Definium Therapeutics, Inc. develops investigational therapeutics for psychiatric and neurological disorders. The company’s news centers on DT120 ODT (lysergide tartrate), its lead Phase 3 program for generalized anxiety disorder and major depressive disorder, along with clinical-trial progress, pre-commercial planning, and updates on the treatment landscape for mood and anxiety disorders.
Recurring announcements also include quarterly and annual financial results, investor and analyst events, research publications related to generalized anxiety disorder, and public-company compensation actions such as Nasdaq inducement grants for new employees.
Definium Therapeutics (NASDAQ: DFTX) will report full year 2025 financial results via a live webcast on Thursday, February 26, 2026 at 4:30 p.m. EST.
The company said the webcast will include a discussion of recent business updates; registration and analyst participation links are provided and a replay will be archived on the Investor Relations website for at least 30 days.
Definium Therapeutics (NASDAQ:DFTX) announced inducement option grants to two newly hired non-executive employees totaling 28,640 common share options with an effective grant date of February 2, 2026. The exercise price equals the closing share price on each grant date.
Vesting is over four years: 25% at the first anniversary and the remaining 75% in substantially equal monthly installments over the following three years, subject to continued employment. The grants were approved by the Compensation Committee on January 29, 2026, granted outside the company’s equity incentive plans in accordance with Nasdaq Rule 5635(c)(4).
Definium Therapeutics (NASDAQ:DFTX) appointed Roger Adsett to its Board of Directors effective January 29, 2026.
Adsett brings more than two decades of commercial and launch experience, including leadership at Insmed, and will support Definium as it approaches three anticipated Phase 3 readouts in 2026.
Definium Therapeutics (NASDAQ:DFTX) announced inducement option grants to three newly hired non-executive employees totaling 88,850 options with effective grant dates of January 12 and January 26, 2025. The exercise price equals the closing price on each grant date. The options vest over four years with 25% on the first anniversary and the remaining 75% monthly over the next three years, subject to continued employment. The grants were approved by the company's Compensation Committee on January 8, 2026 under NASDAQ Rule 5635(c)(4) and were issued outside of Definium's equity incentive plans as material inducements to employment.
Definium Therapeutics (NASDAQ:DFTX) launched Rerouting Minds, an educational campaign to increase understanding of pharmaceutical lysergide (LSD) and the role of rigorous psychedelic research in mental health care. The campaign targets healthcare providers, psychiatrists, therapists, advocates, and policymakers and provides scientific context on LSD’s medical history (dating to 1938), hypothesized brain effects, and community resources. The release cites that nearly 1 in 4 adults (about 59.3 million in the U.S.) live with a mental health disorder and that over 28 million do not receive treatment. Materials and resources are available at www.definiumtx.com/rerouting-minds.
Definium Therapeutics (Nasdaq: DFTX) said its common shares will begin trading on Nasdaq under the new ticker DFTX effective at market open on January 15, 2026. The company previously expected the change on January 13, 2026 and updated the effective date to January 15. Shareholders do not need to take any action for the ticker symbol change.
Definium Therapeutics (NASDAQ:DFTX) announced a rebrand from MindMed and outlined a late-stage psychiatry program led by DT120 orally disintegrating tablet (ODT). The company expects three Phase 3 topline readouts in 2026: Voyage (1st GAD study) in 2Q, Panorama (2nd GAD study) in 2H, and Emerge (1st MDD study) mid-year. DT120 ODT holds FDA Breakthrough Therapy Designation for GAD. Definium plans FDA submissions for GAD and MDD markets, is preparing commercialization readiness, and continues early‑stage work, including dosing the first patient in a Phase 2a DT4023 study for ASD. The Nasdaq ticker changes to DFTX effective January 13, 2026, and the company will webcast a J.P. Morgan Healthcare Conference presentation on January 14, 2026.